Clinical application of gelatin sponge microparticles-transcatheter arterial chemoembolization combined with synchronous antigen-presenting dendritic cell sequential reinfusion for treatment of advanced large liver cancer: A single-center, prospective, non-randomized, controlled trial.
Medicine (Baltimore)
; 101(8): e28803, 2022 Feb 25.
Article
en En
| MEDLINE
| ID: mdl-35212274
ABSTRACT
ABSTRACT To assess the clinical efficacy and safety of gelatin sponge microparticles-transcatheter arterial chemoembolization (GSMs-TACE) plus synchronous antigen-presenting dendritic cell (DC) sequential reinfusion for advanced large liver cancer (LC).Patients with large LC were assigned to the experimental (combined sequential DC therapy) or control group. All patients received standardized GSMs-TACE. In the experimental group, 60âmL of peripheral blood was collected for in vitro culture of DCs (10-14âdays). Then, intravenous reinfusion was conducted 3 times within 10, 20, and 30âdays after surgery. Adverse reactions during the treatment were recorded and evaluated. The overall survival, transcatheter arterial chemoembolization frequency, and physical score (PS) were calculated.The median survival time of the experimental group was significantly longer than that of the control group. There were significant differences in median progression-free survival between the 2 groups (Pâ<â.05) and the objective effective rate at 1 and 6âmonths and 1âyear (Pâ<â.05), but not 2âyears (Pâ>â.05). The PSs of 2 groups were significantly improved at 1âmonth after GSMs-TACE, with more obvious improvement in the experimental group (Pâ<â.05).GSMs-TACE plus synchronous DC sequential reinfusion significantly prolonged the median survival time, improved the tumor response rate and PS, prolonged progression-free survival, and reduced intervention frequency. GSMs-TACE plus synchronous DC sequential reinfusion treatment is suitable for comprehensive treatment of patients with advanced larger LC in China.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Contexto en salud:
1_ASSA2030
/
2_ODS3
Problema de salud:
1_doencas_nao_transmissiveis
/
2_muertes_prematuras_enfermedades_notrasmisibles
Asunto principal:
Células Dendríticas
/
Quimioembolización Terapéutica
/
Carcinoma Hepatocelular
/
Inmunoterapia
/
Neoplasias Hepáticas
Tipo de estudio:
Clinical_trials
/
Etiology_studies
/
Observational_studies
/
Risk_factors_studies
Límite:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Medicine (Baltimore)
Año:
2022
Tipo del documento:
Article
País de afiliación:
China